-
1 Comment
Chong Kun Dang Holdings Corp is currently in a long term downtrend where the price is trading 0.4% below its 200 day moving average.
From a valuation standpoint, the stock is 93.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Chong Kun Dang Holdings Corp's total revenue rose by 13.9% to $216B since the same quarter in the previous year.
Its net income has increased by 257.5% to $31B since the same quarter in the previous year.
Finally, its free cash flow fell by 68.3% to $-23B since the same quarter in the previous year.
Based on the above factors, Chong Kun Dang Holdings Corp gets an overall score of 3/5.
| ISIN | KR7001630003 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers-Specialty & Generic |
| CurrencyCode | KRW |
| Exchange | KO |
| Market Cap | 252B |
|---|---|
| Beta | 0.5 |
| Dividend Yield | 2.7% |
| Target Price | 140000 |
| PE Ratio | None |
Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 001630.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
